Luye Pharma Group logo

Luye Pharma Group(SEHK) 2186

Market CapHK$6.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-73%
5 Year-57%
1 Year-48%
1 Month-5%
HK$1.70
-0.58%
-0.01Today
Luye Pharma Group last closing stock price
MetricPriceDate
Last closeHKD 1.702026-10-14
Luye Pharma Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.03%HKD 1.792026-10-07
1 month-5.03%HKD 1.792026-09-14
3 month-23.42%HKD 2.222026-07-16
Year to date-37.96%HKD 2.742025-12-31
1 year-47.69%HKD 3.252025-10-14
3 year-51.98%HKD 3.542023-10-13
5 year-56.52%HKD 3.912021-10-15
Since inception-72.59%HKD 6.242014-07-09

Luye Pharma Group Financials at a Glance

Market Cap

HK$6.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥12.30B

Net Income (TTM)

CN¥1.09B

EPS (TTM)

HK$0.13

P/E Ratio

8.70

Dividend

HK$0.00

Beta (Volatility)

0.07 (Low)

Price

HK$1.70

Volume

11,524,798

Open

HK$1.73

Previous Close

HK$1.71

Daily Range

HK$1.68 - HK$1.73

52-Week Range

HK$1.66 - HK$3.69

Estimated Earnings Date

Mar 31, 2027

2186 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Luye Pharma Group

Luye Pharma Group Ltd. is a global investment holding enterprise specializing in the development, production, marketing, and sales of pharmaceutical products. The company offers a diverse portfolio, particularly in oncology, metabolic health, and neurological therapeutics.

Products and Services
  • Key oncology treatments including Lipusu and Tiandida
  • Metabolic health products like Xuezhikang and Beitangning
  • Neurological therapeutics including Rivastigmine and Seroquel
Growth Outlook
  • Strong demand for oncology products drives revenue growth
  • Expansion into international markets enhances market presence
  • Investment in R&D supports innovative product development
Financial Highlights
  • Q2 2026 revenue of CNY 2.96 billion, reflecting solid performance
  • Net income margin of 13% indicates effective cost management
  • TTM P/E ratio of 9.38 suggests potential undervaluation
Luye Pharma Group Ltd. has established itself as a significant player in the pharmaceutical industry, particularly in oncology and metabolic health. The company's commitment to research and development is evident in its diverse product offerings, which cater to various therapeutic areas. Recent financial performance highlights a robust revenue stream and effective cost management, positioning the company favorably for future growth. The ongoing expansion into international markets and a focus on innovative product development further enhance its growth prospects. With a competitive P/E ratio, Luye Pharma presents an intriguing opportunity for potential investors looking to explore the pharmaceutical sector.
AI Generated • Oct 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5,221

CEO

Dian Bo Liu

Website

www.luye.cn

Headquarters

Yantai, GD 264003, CN

2186 Financials

Key Financial Metrics (TTM)

Gross Margin

63.75%

Operating Margin

18.49%

Net Income Margin

11.36%

Return on Equity

4.40%

Return on Capital

4.87%

Return on Assets

2.00%

Earnings Yield

11.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$6.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.99B

Volume

11.52M

Avg. Volume

31.37M

Financials (TTM)

Gross Profit

CN¥8.03B

Operating Income

CN¥2.25B

EBITDA

CN¥3.78B

Operating Cash Flow

CN¥3.31B

Capital Expenditure

-CN¥1.16B

Free Cash Flow

CN¥2.15B

Cash & ST Invst.

CN¥13.33B

Total Debt

CN¥12.54B

Luye Pharma Group Performance Analysis

Luye Pharma Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 6,955,937,35011.0%
20232023-12-31CNY 6,788,088,887-2.4%
20242024-12-31CNY 6,571,958,852-3.2%
20252025-12-31CNY 6,841,579,0344.1%
Luye Pharma Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-2.9%
Q22025-06-306.5%
Q42025-12-31-1.7%
Q22026-06-30-4.0%
Luye Pharma Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.20N/A
20232023-12-31CNY 0.16-21.9%
20242024-12-31CNY 0.14-13.8%
20252025-12-31CNY 0.1726.6%
Luye Pharma Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-77.7%
Q22025-06-30273.1%
Q42025-12-31-8.8%
Q22026-06-3028.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥3.00B

-2.4%

Gross Profit

CN¥1.90B

-8.5%

Gross Margin

63.36%

N/A

Market Cap

HK$6.79BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$1.29M

N/A

Employees

5,270

N/A

Net Income

CN¥390.49M

+0.7%

EBITDA

CN¥877.57M

-7.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥13.33B

+105.7%

Total Debt

CN¥12.54B

+32.7%

Accounts Receivable

CN¥3.29B

+27.7%

Inventory

CN¥1.11B

+35.9%

Long Term Debt

CN¥2.84B

+2.2%

Short Term Debt

CN¥9.74B

+46.0%

Return on Assets

2.00%

N/A

Return on Invested Capital

5.09%

N/A

Free Cash Flow

CN¥624.35M

+258.3%

Operating Cash Flow

CN¥624.35M

+258.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$50.66-6.11%
CRWVCoreWeave
$65.56-15.74%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$42.27+12.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.20-12.83%

Questions About 2186

What is the current price of Luye Pharma Group?

Luye Pharma Group is trading at HK$1.70 per share.

What is the 52-week range for Luye Pharma Group?

Over the past 52 weeks, Luye Pharma Group has traded between HK$1.66 and HK$3.69.

How much debt does Luye Pharma Group have?

As of the most recent reporting period, Luye Pharma Group reported total debt of CN¥10.49B.

How much cash does Luye Pharma Group have on hand?

Luye Pharma Group reported CN¥6.18B in cash and cash equivalents in its most recent financial results.

What is Luye Pharma Group’s dividend yield?

Luye Pharma Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services